The impact of antidepressant-associated sexual dysfunction on treatment adherence in patients with major depressive disorder

Current Psychiatry Reviews

Volumn 9, Issue 4, 2013, Pages 293-301

  Clayton, Anita H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antidepressant induced sexual dysfunction; Depression; Major depressive disorder; Side effects; Treatment nonadherence

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANORGASMIA; ARIZONA SEXUAL EXPERIENCES SCALE; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE; HUMAN; MAJOR DEPRESSION; MEDICATION COMPLIANCE; ORGASM; ORGASM DISORDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION;

EID: 84888099605     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/15734005113096660007     Document Type: Review

References (78)

1. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164(2): 201-4.
2. Shim RS, Baltrus P, Ye J, Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. J Am Board Fam Med 2011; 24(1): 33-8.
3. Kessler RC, Bergland P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey replication (NSC-R). JAMA 2003; 289(23): 3095-105.
4. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenterstudy of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62(suppl3): 10-21.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281(6): 537-44. Erratum in: JAMA 1999; 281(13): 1174.
6. Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004; 1(1): 35-9.
7. Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry 2009; 70(12): 1698-1706.
8. Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19(2): 114-124.
9. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgemont) 2009; 6(2): 16-8.
10. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
11. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressantrelated adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res 2005; 66(2): 96-106.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed., text revision). Washington, DC: APA; 2000.
13. Bossini L, Fagiolini A, Valdagno M, Polizzotto NR, Castrogiovanni P. Sexual disorders in subjects treated for mood and anxiety diseases. J Clin Psychopharmacol 2007; 27(3): 310-2.
14. Fabre LF, Smith LC. The effect of major depression on sexual function in women. J Sex Med 2012; 9(1): 231-9.
15. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev 2009; 29(7): 573-85.
16. Menezes A, Artham S, Lavie CJ, Milani RV, O'Keefe J. Erectile dysfunction and cardiovascular disease. Postgrad Med 2011; 123(3): 7-16.
17. Chughtai B, Lee RK, Te AE, Kaplan SA. Metabolic syndrome and sexual dysfunction. Curr Opin Urol. 2011; 21(6): 514-8.
18. Manolis A, Doumas M. Sexual dysfunction: the 'prima ballerina' of hypertension-related quality-of-life complications. J Hypertens 2008; 26(11): 2074-84.
19. Wallwiener CW, Wallwiener LM, Seeger H, Mück AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med 2010; 7(B): 2138-41.
20. Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med 2006; 3(1): 104-13.
21. Clayton AH, Ramamurthy S. The impact of physical illness on sexual dysfunction. In: Balon R, Ed. Sexual Dysfunction. The Brain-Body Connection. (Adv Psychosom Med.) Basel: Karger; 2008; 29: pp. 77-88.
22. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRIinduced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23(3): 176-94.
23. Haberfellner EM. A review of the assessment of antidepressantinduced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 2007; 40(5): 173-82.
24. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997; 33(4): 747-53.
25. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009; 29(2): 157-64.
26. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997; 33(4): 731-45.
27. Dunn JA, Arakawa R, Greist JH, Clayton AH. Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology. J Clin Psychiatry 2007; 68(4): 525-32.
28. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26(1): 25-40.
29. Derogatis LR. The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. J Sex Marital Ther 1997; 23(4): 291-304.
30. Montejo AL, Garcia M, Espada M, Rico-Villademoros F, Llorcva G, Izquierdo JA. [Psychometric characteristics of the psychotropicrelated sexual dysfunction questionnaire. Spanish Work Group for the Study of Psychotropic-Related Sexual Dysfunctions.] Actas Esp Psiquiatr 2000; 28(3): 141-50. [In Spanish].
31. Sleath B, Wurst K, Lowery T. Drug information sources and antidepressant adherence. Community Ment Health J 2003; 39(4): 359-68.
32. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63(4): 357-66.
33. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29(3): 259-66.
34. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4(4 pt 1): 917-29.
35. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67(5): 736-46.
36. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26(5): 482-8.
37. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction duringtreatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61(4): 276-81.
38. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006; 91(1): 27-32.
39. Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr 2009; 14(12suppl 12): 8-14.
40. Zimmerman M, Galione JN, Attiulah N, et al. Underrecognition of clinically significant side effects in depressed outpatients. J Clin Psychiatry 2010; 71(4): 484-90.
41. Venturini F, Sung J, Nichol M, et al. Utilization patterns of antidepressant medications in a patient population served by a primary care medical group. J Manag Care Pharm 1999; 5: 243-9.
42. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21(4): 643-58.
43. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994; 8(1): 48-52.
44. Lin EH, VonKorff M, Lin E, et al. The role of the primary care physician in patient's adherence to antidepressant therapy. Med Care 1995; 33(1): 67-74.
45. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15(6): 399-408.
46. Ereshefsky L, Saragoussi D, Despiégel N, Hansen K, François C, Maman K. The 6-month persistence on SSRIs and associated economic burden. J Med Econ 2010; 13(3): 527-36.
47. Wetherell JL. Unutzer J. Adherence to treatment for geriatric depression and anxiety. CNS Spectr. 2003; 12(suppl 3): 48-59.
48. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf 2010; 2: 141-50.
49. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28(3): 329-33.
50. Clayton AH, Campbell BJ, Favit A, et al. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. J Clin Psychiatry 2007; 68(12): 1860-6.
51. Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/SNRIinducedsexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31(3): 257-62.
52. Ashton AK. Reversal of fluoxetine-induced sexual dysfunction by switching to escitalopram [letter]. J Sex Marital Ther 2004; 30(1): 1-2.
53. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006; 20(1): 91-96.
54. Langworth S, Bodlund O, Ågren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 2006; 26(2): 121-7.
55. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998; 59(3): 112-5.
56. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63(3): 181-6.
57. Gitlin MJ, Suri R, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther 2002; 28(2): 131-8.
58. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65(1): 62-7.
59. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999; 19(3): 268-71.
60. Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000; 157(2): 239-43.
61. Dolberg OT, Klag E, Gross Y, Schreiber S. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with lowdose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl) 2002; 161(4): 404-7.
62. Ravindran LN, Eisfeld BS, Kennedy SH. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function. J Clin Psychopharmacol 2008; 28(1): 107-8.
63. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003; 289(1): 56-64.
64. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressantassociated sexual dysfunction: a randomized controlled trial. JAMA 2008; 300(4): 395-404.
65. Berigan T. Antidepressant-induced sexual dysfunction treated with vardenafil. Can J Psychiatry 2004; 49(9): 643.
66. Ashton AK. Vardenafil reversal of female anorgasmia. Am J Psychiatry 2004; 161(11): 2133.
67. Rosen R, Shabsigh R, Berber M, et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006; 163(1): 79-87.
68. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011; 31(5): 643-6.
69. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, doubleblind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011; 72(4): 441-7.
70. Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 2012; Dec 6. [Epub ahead of print].
71. Moore NA, Bang-Andersen B, Brennum LT, et al. Lu AA21004: a novel potential treatment for mood disorders. Eur Neuropsychopathol 2008; 18(suppl 4): S321.
72. Prins J, Denys DA, Westphal KG, et al. The putative antidepressant DOV 216, 303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol 2010; 633(1-3): 55-61.
73. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A-1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006; 31(10): 2281-8.
74. Bishop JR, Ellingrod VL, Akroush M, Moline J. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol 2009; 24(3): 207-15.
75. Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009; 34: 1891-28.
76. Kubota T, Miyake K, Hirasawa T. Epigenetic understanding of gene-environment interactions in psychiatric disorders; a new concept of clinical genetics. Clin Epigenetics 2012; 4: 1.
77. Burri A, Greven C, Leupin M, Spector T, Rahman Q. A multivariate twin study of female sexual dysfunction. J Sex Med 2012; 9: 2671-81.
78. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288(11): 1403-9.